Study Status: Not yet recruiting
Recruit Status: Not yet recruiting
Study Type: Interventional
Official Title: A Randomized Phase 2 Study of Varlilumab (CDX-1127) in Combination With Nivolumab in Patients With Relapsed or Refractory Aggressive B-Cell Lymphomas
Brief Summary: This randomized phase II trial studies how well nivolumab with or without varlilumab works in treating patients with aggressive B-cell lymphomas that have come back or do not respond to treatment. Monoclonal antibodies, such as varlilumab and nivolumab, may work by stimulating the immune system to attack cancer tumor cells.